Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Building R&D Capabilities In China – Spotlight On Pfizer

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Multinational pharmaceutical companies have moved beyond debating whether to open R&D operations in China to debating whether to open "brick and mortar" operations or "virtual" operations via outsourcing, according to speakers at the China 2008 Pharmaceutical R&D Summit in Shanghai

You may also be interested in...



Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference

SINGAPORE - As big pharma looks across Asia for new ways of doing business, execs from the top pharma companies agreed that having people on the ground in Asia is critical and that companies are moving away from being fully integrated pharma companies to becoming fully integrated pharma networks

Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference

SINGAPORE - As big pharma looks across Asia for new ways of doing business, execs from the top pharma companies agreed that having people on the ground in Asia is critical and that companies are moving away from being fully integrated pharma companies to becoming fully integrated pharma networks

GSK Jumps Into Growing China R&D Space

GlaxoSmithKline has joined a growing list of big pharma companies expanding in China, launching a research and development center based in Shanghai, the company announced May 24

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel